Litcius/Paper detail

Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial

Mitsue Saito, Hirotoshi Iihara, Mototsugu Shimokawa, Ryoko Udagawa, Michiko Tsuneizumi, Manabu Futamura, Yuko Ishikawa, Hideaki Ogata, Hiroko Bando, Hiroaki Shima, Keiko Hosoya, Toru Mukohara, Ken-ichiro Tanaka, Tomoki Ikuta, Takahiko Kawate, Kazushige Ishida, Katsuya Nakai, Toshitaka Uomori, Goro Kutomi, Rie Ozeki, Naotake Yanagisawa

2025The Lancet Oncology12 citationsDOI

Topics & Concepts

MedicineOlanzapineRegimenPlaceboAnthracyclineInternal medicinePhases of clinical researchRandomized controlled trialOncologyClinical trialCancerBreast cancerPsychiatrySchizophrenia (object-oriented programming)Alternative medicinePathologyNausea and vomiting managementChemotherapy-induced organ toxicity mitigationEnhanced Recovery After Surgery